Forteo Voluntary Patient Registry: 4-Year Progress on a Prospective Osteosarcoma Surveillance Study

Krohn, Kelly; Kellier, N; Masica, Daniel N.; Gilsenan, Alicia; Harding, Abenah; Andrews, Elizabeth

doi:10.1016/j.jocd.2014.04.105

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Accordingly, 18 articles were included in our study. 1 , 3 , 14–29 7 out of the 18 studies are prospective studies, 14–16 , 18 , 24 , 25 , 29 5 are cohort studies, 1 , 17 , 26–28 2 are retrospective case-series studies, 3 , 19 3 are randomized controlled trials, 20 , 21 , 23 and 1 is a follow up study. 22 All of the included articles underwent extensive qualitative and quantitative evidence synthesis to establish their quality.…”

Section: Resultsmentioning

confidence: 99%

The Risk of Developing Osteosarcoma After Teriparatide Use: A Systematic Review

Abdulelah,

Haddad,

Alhajahjeh

et al. 2023

ORR

View full text Add to dashboard Cite

Teriparatide is a recombinant human parathyroid hormone analog with anabolic mechanism of action utilized in the treatment of osteoporosis with well-established clinical efficacy. Its use is significantly hindered due to label warnings resulting from pre-clinical rat studies demonstrating an increased risk of osteosarcoma. However, clinical trials and post-marketing surveillance studies did not demonstrate any increased risk of osteosarcoma, even after prolonged periods of surveillance reaching up to 15 years, with most of the identified cases of osteosarcomas being solitary and predominantly attributed to other factors. This systematic review provides a comprehensive overview of the currently available literature and provides the highest level of clinical evidence towards demonstrating the lack of any substantial evidence towards osteosarcoma development in patients utilizing TPTD.

show abstract